MacuSight, Inc. Receives Fast Track Designation From FDA for Perceiva(TM) in Treatment of Diabetic Macular Edema
10/21/2009 9:46:26 AM
More...
|
MacuSight, Inc. Provides Clinical Development Update for Perceiva(TM) Four Phase 2 Clinical Trials in Major Ocular Diseases Fully Enrolled; Data Available in First Half of 2010
9/30/2009 10:37:43 AM
More...
|
etrials Chosen by MacuSight, Inc. as its EDC and IVR Solutions Provider On Three Ophthalmology Studies
4/16/2009 8:39:55 AM
More...
|
MacuSight, Inc. Appoints Gerald Wroblewski Vice President of Operations Move Adds Key Manufacturing Expertise as Company Broadly Advances Sirolimus Clinical Development
11/6/2008 10:59:29 AM
More...
|
Santen Pharmaceutical and MacuSight, Inc. Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions; MacuSight to Receive Upfront $50 Million
6/2/2008 8:59:24 AM
More...
|
MacuSight, Inc. Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration Sirolimus Demonstrates Favorable Safety Profile and Improvements in Visual Acuity
2/25/2008 7:42:28 AM
More...
|
MacuSight, Inc. Expands Management Team With Appointment of Dr. Joel Naor as Chief Medical Officer
2/20/2008 9:01:41 AM
More...
|
MacuSight, Inc. Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
10/1/2007 8:38:49 AM
More...
|
MacuSight, Inc. Appoints Brian C. Cunningham To Board Of Directors
11/2/2006 11:12:49 AM
More...
|
MacuSight, Inc. Initiates Wet Age-Related Macular Degeneration Study
10/31/2006 11:13:21 AM
More...
|
|